Trial reportBMC psychiatry2025
Application of PANSS-6 in the assessment of severity and improvement in patients with schizophrenia: a clinical antipsychotic trial of effectiveness.
Trial report in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe positive and negative syndrome scale (PANSS) has long been used in the assessment of patients with schizophrenia; however, its lengthy administration process, which can even exceed an hour, has led to interest in developing a shorter version. PANSS-6 was created as a more efficient and streamlined alternative, and in this study, we aimed to evaluate its application in assessing severity and improvement in patients with schizophrenia undergoing a multicenter, open-label study of paliperidone.
methodsA total of 271 patients aged 18–60 years with a DSM-IV diagnosis of schizophrenia participated in the study. Over a 6-week observation period, patients received paliperidone monotherapy and underwent clinical assessments using PANSS. The study conducted a comprehensive analysis of internal consistency, the effectiveness of antipsychotic treatment, response and remission assessments, and early response prediction, comparing PANSS-6 with PANSS-30.
resultsPANSS-6 showed good reliability and was highly correlated with PANSS-30. It was effective in evaluating the severity of schizophrenia and monitoring the score reduction over time. We observed no significant difference in the mean effect sizes (ES) between PANSS-6 and PANSS-30. Furthermore, using PANSS-6, early response at week 2 was found to be predictive of ultimate response and remission at week 6.
conclusionIn this study, PANSS-6 demonstrated good internal consistency and a strong correlation with PANSS-30. These findings support its value for assessing treatment outcomes and predicting early response in patients with schizophrenia undergoing antipsychotic therapy. The use of PANSS-6 may offer a practical and streamlined method for symptom monitoring in clinical settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.